Ironwood Pharmaceuticals Inc.

(IRWD) Trade

By |

Profile

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Contact Information

Website: www.ironwoodpharma.com
Email: mkaya@ironwoodpharma.com
Main Phone: +1 617 621-7722
Address: 100 Summer Street
Address 2: Suite 2300
State: MA
City / Town: Boston
Country: US
Postal Code: 02110

Issuer Information

Exchange: NGS
CEO: Mark Mallon
Employees: 317
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

Profile

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Contact Information

Website: www.ironwoodpharma.com
Email: mkaya@ironwoodpharma.com
Main Phone: +1 617 621-7722
Address: 100 Summer Street
Address 2: Suite 2300
State: MA
City / Town: Boston
Country: US
Postal Code: 02110

Issuer Information

Exchange: NGS
CEO: Mark Mallon
Employees: 317
NAICS: Pharmaceutical Preparation Manufacturing(325412)

Equities News

$ 9.64 $ 0.15 (1.58%)
Last Price 9.64 Change $ 0.15 Change % 1.58 Tick N/A
Bid 8.57 Bid Size 300.00 Ask 10.90 Ask Size 500.00
Open 9.54 High 9.67 Low 9.26 Prev Close 9.49
Last Trade Volume 1.8 mi 52 Wk Hi 14.11 52 Wk Low 7.99
Market Cap 1.5 bi Ex-Div Date N/A Div Rate N/A Yield N/A
Shares 159,978,137.00 EPS (TTM) 0.62 PE Ratio 15.30 Exchange NGS
  Last 3 Mo Last 12 Mo
Number of Insider Trades 10 39
Number of Buys 8 17
Number of Sells 2 22
Net Activity 126284 248000
Last 10 Buys Shares
Edward P. Owens 1,000
Peter M. Hecht 1,000
Last 10 Sell Shares
Lawrence S. Olanoff 1,000
Julie H. McHugh 1,000
Lawrence S. Olanoff 1,000
Julie H. McHugh 1,000
Thomas A. McCourt 1,000
Gina Consylman 1,000
Halley E. Gilbert 1,000
Mark G. Currie 1,000
Gina Consylman 1,000
Gina Consylman 1,000
  Current 1 Week Ago 2 Weeks Ago 3 Weeks Ago
High Target Price Estimate 20 20 20 20
Low Target Price Estimate 13 13 13 13
Mean Target Price Estimate 17.25 17 17 17.25
Standard Deviation 2.55 2.33 2.33 2.55
Date of Most Recent Estimate 05/31/18 05/09/18 05/09/18 06/08/18
  Current 1 Month Ago 2 Months Ago 3 Months Ago
Strong Buy 3 3 2 2
Moderate Buy 0 0 0 0
Hold 3 3 4 4
Moderate Sell 1 1 1 1
Strong Sell 1 1 0 0
Mean Rec. 2.54 2.54 2.57 2.57